{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:48:41Z","timestamp":1785419321178,"version":"3.56.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To study a possible relationship between hyperparathyroidism and osteosarcoma, we reviewed 1234 osteosarcoma patients. In this cohort, only three patients had a diagnosis of both hyperparathyroidism and fibroblastic osteosarcoma. These results indicate that hyperparathyroidism is not more prevalent in patients with osteosarcoma than in the general population. However, the presence of hyperparathyroidism may modify the histologic and cytologic features of osteosarcoma.<\/jats:p>\n               <jats:p>Introduction: The finding of osteosarcoma in rats receiving human PTH(1-34) raised the question of whether hyperparathyroidism might be a risk factor for development of osteosarcoma in humans.<\/jats:p>\n               <jats:p>Materials and Methods: To study a possible relationship between hyperparathyroidism and osteosarcoma, we reviewed the medical records of 1234 osteosarcoma patients seen at The M.D. Anderson Cancer Center since 1948. Our study focused on clinical, biochemical, radiologic, and histopathologic findings indicative of primary hyperparathyroidism and the features of osteosarcoma.<\/jats:p>\n               <jats:p>Results: Of the 1234 cases reviewed, 3 patients had a diagnosis of both primary hyperparathyroidism and osteosarcoma. In two cases, hyperparathyroidism preceded the osteosarcoma, and in one case, both conditions were diagnosed at the same time. In two cases with concomitant hyperparathyroidism and osteosarcoma, features of osteitis fibrocystica were identified. The third patient was treated for hyperparathyroidism 3 years before osteosarcoma was diagnosed. All three patients had histologic features of fibroblastic osteosarcoma, a type that accounts for no more than 20% of osteosarcomas. To assess whether the prevalence of hyperparathyroidism was greater than expected in the normal population, we compared the age- and sex-specific prevalence in our cohort to a population of healthy individuals in Tromso, Norway. This analysis showed no significant differences between the two populations, despite the fact that a higher prevalence of hyperparathyroidism (6.9% versus 1.6%) was noted in the 60- to 69-year-old female osteosarcoma age group.<\/jats:p>\n               <jats:p>Conclusions: Our results indicate that hyperparathyroidism is not more prevalent in affected individuals with osteosarcoma than in the general population. The finding of fibroblastic osteosarcoma in all three patients raises the question of whether coexistent hyperparathyroidism may modify the cytologic and histologic features of the malignancy.<\/jats:p>","DOI":"10.1359\/jbmr.050507","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T09:09:23Z","timestamp":1146128963000},"page":"1562-1568","source":"Crossref","is-referenced-by-count":16,"title":["Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Three Cases of Fibroblastic Osteosarcoma"],"prefix":"10.1093","volume":"20","author":[{"given":"Camilo","family":"Jimenez","sequence":"first","affiliation":[{"name":"The Bone Disease Program of Texas, Houston, Texas, USA"},{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fozia","family":"Al-Sagier","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel K.","family":"El-Naggar","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Vassilopoulou-Sellin","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Gagel","sequence":"additional","affiliation":[{"name":"The Bone Disease Program of Texas, Houston, Texas, USA"},{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019252609300_bib1","first-page":"264","volume-title":"Pathology and Genetics of Tumors of Soft Tissue and Bone","author":"Raymond","year":"2002"},{"key":"2024013019252609300_bib2","first-page":"230","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"Bilezikian","year":"2003","edition":"5th ed."},{"key":"2024013019252609300_bib3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2024013019252609300_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/jbmr.2003.18.1.163","article-title":"Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report","volume":"18","author":"Betancourt","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019252609300_bib5","first-page":"391","article-title":"Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report","volume":"137","author":"Wiig","year":"1971","journal-title":"Acta Chir Scand"},{"key":"2024013019252609300_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002560050202","article-title":"Hyperparathyroidism associated with sarcoma of bone","volume":"26","author":"Smith","year":"1997","journal-title":"Skeletal Radiol"},{"key":"2024013019252609300_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00405-002-0497-3","article-title":"Neurofibromatosis type 1, hyperparathyroidism, and osteosarcoma: Interplay?","volume":"259","author":"Cinamon","year":"2002","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1 Suppl","key":"2024013019252609300_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V","article-title":"Bone cancers","volume":"75","author":"Dorfman","year":"1995","journal-title":"Cancer"},{"key":"2024013019252609300_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.0954-6820.1976.tb08208.x","article-title":"Prevalence of hypercalcaemia in a health screening in Stockholm","volume":"200","author":"Christensson","year":"1976","journal-title":"Acta Med Scand"},{"key":"2024013019252609300_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.1992.tb00540.x","article-title":"Serum ionized calcium and the prevalence of primary hyperparathyroidism in age cohorts of 75, 80 and 85 years","volume":"231","author":"Sorva","year":"1992","journal-title":"J Intern Med"},{"key":"2024013019252609300_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","journal-title":"Surgery"},{"key":"2024013019252609300_bib12","first-page":"189","article-title":"Primary hyperparathyroidism","volume":"302","author":"Heath","year":"1980","journal-title":"Incidence, morbidity, and potential economic impact in a community. N Engl J Med"},{"key":"2024013019252609300_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2362.1988.tb01163.x","article-title":"Prevalence of hypercalcaemia in a health survey: A 14-year follow-up study of serum calcium values","volume":"18","author":"Palmer","year":"1988","journal-title":"Eur J Clin Invest"},{"key":"2024013019252609300_bib14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0895-4356(00)00239-0","article-title":"Primary hyperparathyroidism detected in a health screening. The Tromso study","volume":"53","author":"Jorde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"2024013019252609300_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"2024013019252609300_bib16","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024013019252609300_bib17","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"BMJ"},{"key":"2024013019252609300_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02556561","article-title":"Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients","volume":"44","author":"Hesch","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"2024013019252609300_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01625448","article-title":"hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses","volume":"1","author":"Reeve","year":"1991","journal-title":"Osteoporos Int"},{"key":"2024013019252609300_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA"},{"key":"2024013019252609300_bib21","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019252609300_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024013019252609300_bib23","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019252609300_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019252609300_bib25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/B978-012470862-4\/50078-7","volume-title":"Osteoporosis","author":"Mosekilde","year":"2001","edition":"2nd ed."},{"key":"2024013019252609300_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(99)00166-0","article-title":"Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"25","author":"Jerome","year":"1999","journal-title":"Bone"},{"key":"2024013019252609300_bib27","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1210\/endo.138.10.5440","article-title":"Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats","volume":"138","author":"Sato","year":"1997","journal-title":"Endocrinology"},{"key":"2024013019252609300_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"2024013019252609300_bib29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1359\/jbmr.2002.17.7.1151","article-title":"Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women","volume":"17","author":"Tashjian","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019252609300_bib30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","article-title":"Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study","volume":"104","author":"Rindi","year":"1993","journal-title":"Gastroenterology"},{"key":"2024013019252609300_bib31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM199912023412304","article-title":"Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor","volume":"341","author":"Liu","year":"1999","journal-title":"N Engl J Med"},{"key":"2024013019252609300_bib32","doi-asserted-by":"crossref","first-page":"D343","DOI":"10.2741\/Wu","article-title":"Luteinizing hormone receptor mutations in disorders of sexual development and cancer","volume":"5","author":"Wu","year":"2000","journal-title":"Front Biosci"},{"key":"2024013019252609300_bib33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1210\/jcem.87.3.8294","article-title":"Male LH-independent sexual precocity in a 3.5-year-old boy caused by a somatic activating mutation of the LH receptor in a Leydig cell tumor","volume":"87","author":"Richter-Unruh","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019252609300_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.0.1470109","article-title":"Expression of G(alpha)(s) proteins and TSH receptor signalling in hyperfunctioning thyroid nodules with TSH receptor mutations","volume":"147","author":"Holzapfel","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2024013019252609300_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1010076706666","article-title":"Thyrotropin receptor mutations in thyroid diseases","volume":"1","author":"Yen","year":"2000","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050507","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/9\/1562\/56477424\/5650200908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/9\/1562\/56477424\/5650200908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:09:29Z","timestamp":1710342569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/9\/1562-1568\/7593071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,1]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050507","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,9,1]]},"published":{"date-parts":[[2005,9,1]]}}}